SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer
The purpose of this study is to evaluate the progression-free survival (PFS) of Chemotherapy combined with SHR-1316 in patients with advanced esophageal squamous cell cancer.
Advanced Esophageal Squamous Cell Cancer
DRUG: Irinotecan liposome|DRUG: SHR-1316|DRUG: Fluorouracil
Duration of Progression-Free Survival (PFS), based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), approximately 22 months
Disease Control Rate(DCR), based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), approximately 22 months|Objective Response Rate(ORR), based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), approximately 22 months|Overall Survival(OS), OS is defined as the time from registration to death due to any cause, or censored at date last known alive., approximately 22 months|Adverse Events(AE), adverse events, approximately 22 months
The purpose of this study is to evaluate the progression-free survival (PFS) of Chemotherapy combined with SHR-1316 in patients with advanced esophageal squamous cell cancer.